[PDF][PDF] Nuclear medicine beyond VISION

WP Fendler, K Herrmann, M Eiber - Journal of Nuclear Medicine, 2021 - Soc Nuclear Med
In March 2021, Novartis announced a positive result for both primary endpoints of the
randomized phase III VISION study on 177Lu-PSMA-617 radioligand therapy (RLT). 177Lu …

Prostate cancer treatment: 177Lu-PSMA-617 considerations, concepts, and limitations

O Sartor, K Herrmann - Journal of Nuclear Medicine, 2022 - Soc Nuclear Med
The phase III VISION trial using 177Lu-PSMA-617 has significant implications for the field of
theranostics and broad repercussions for the clinical management of prostate cancer …

[PDF][PDF] Clinical implementation of 177Lu-PSMA-617 in the United States: lessons learned and ongoing challenges

P Ravi, B Whelpley, E Kelly, A Wolanski… - Journal of Nuclear …, 2023 - Soc Nuclear Med
In March 2022, 177Lu-PSMA-617 (177Lu-vipivotide tetraxetan) received Food and Drug
Administration approval for treatment of metastatic castration-resistant prostate cancer …

Acceleration of PSMA-targeted theranostics to the clinic: can common sense prevail?

J Czernin, M Eiber - Journal of Nuclear Medicine, 2017 - Soc Nuclear Med
The success of targeting and exploiting the prostate-specific membrane antigen (PSMA) for
diagnosis and radioligand therapy of prostate cancer has been remarkable. Unlike in early …

How many theranostics centers will we need in the United States?

J Czernin, J Calais - Journal of Nuclear Medicine, 2022 - Soc Nuclear Med
Lutetium-177-PSMA-617 (PLUVICTO) has been approved by the US Food and Drug
Administration for patients with prostatespecific membrane antigen (PSMA)–positive …

The imperative for comparative studies in nuclear medicine: elevating 177Lu-PSMA-617 in the treatment paradigm for mCRPC

K Rahbar, M Boegemann - Journal of Nuclear Medicine, 2024 - Soc Nuclear Med
Nuclear medicine, with its ever-evolving spectrum of diagnostic and therapeutic
interventions, plays a pivotal role in the multidisciplinary approach to cancer care. In recent …

[PDF][PDF] The 177Lu-PSMA-617 (Pluvicto) supply problem will be solved by competition

J Czernin, J Calais - Journal of Nuclear Medicine, 2023 - Soc Nuclear Med
An editorial in this issue of The Journal of Nuclear Medicine by the theranostics teams of
Dana–Farber Cancer Institute and Brigham and Women's Hospital addresses ongoing …

[PDF][PDF] Bringing VISION to Nuclear Medicine: Accelerating evidence and changing paradigms with theranostics

MS Hofman - Journal of Nuclear Medicine, 2021 - Soc Nuclear Med
(PSMA) as a game-changing target for nuclear medicine at the 2011 European Association
of Nuclear Medicine meeting in Birmingham. The target had been identified 2 decades …

From NETTER to PETTER: PSMA-targeted radioligand therapy

M Eiber, K Herrmann - Journal of nuclear medicine, 2017 - Soc Nuclear Med
In this month's issue of The Journal of Nuclear Medicine, Rahbar et al. present exciting
retrospective German multicenter data (12 centers) on the performance of prostate-specific …

629P Patient-reported outcomes in prostate cancer patients receiving PSMA-targeted radionuclide therapy

BD Gonzalez, MI Sun, C Thomas, S Eisel… - Annals of …, 2021 - annalsofoncology.org
Background Prostate-specific membrane antigen (PSMA) targeted radionuclide therapy
(TRT) is a promising investigational therapy for patients with progressive metastatic …